Skip to main content

Table 10 Hazard ratios (CCLG vs. GPOH) according to local treatment modality, among patients with localised disease only

From: Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

  Local treatment modality Subdivision of RT and surgery group
Radiotherapy (RT) alone
N = 108
Surgery alone
N = 119
RT and surgery
N = 221
RT then surgery
N = 152
Surgery then RT
N = 69
No. events
 EFS 62 42 83 61 22
 OS 53 33 66 49 17
Unadjusted
 EFS 0.89 (0.54–1.46) 1.44 (0.78–2.64) 1.66 (0.94–2.96) 2.44 (0.76–7.81) 2.36 (1.02–5.45)
 OS 0.99 (0.56–1.64) 1.74 (0.86–3.51) 1.60 (0.84–3.06) 2.70 (0.84–8.73) 2.03 (0.78–5.28)
Adjusted for age, primary site and histology
 EFS 0.98 (0.58–1.66) 1.51 (0.78–2.94) 1.65 (0.91–2.99) 2.39 (0.71–8.05) 2.12 (0.83–5.40)
 OS 1.10 (0.62–1.95) 1.94 (0.89–4.25) 1.50 (0.77–2.93) 3.10 (0.90–10.70) 1.74 (0.60–5.08)
Adjusted for age, primary site, histology and time between the start of chemotherapy and starting local treatment
 EFS 0.95 (0.54–1.67) 1.48 (0.76–2.89) 1.48 (0.81–2.69) 1.69 (0.50–5.68) 2.10 (0.82–5.41)
 OS 1.03 (0.55–1.90) 1.92 (0.87–4.24) 1.39 (0.71–2.74) 2.49 (0.72–8.58) 1.74 (0.59–5.10)
  1. Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
  2. Based on data excluding patients with unknown primary site because there were so few
  3. EFS event-free survival; OS overall survival